



Qty: 200 µg/400 µl

Mouse anti-Cyclin E

Catalog No. 32-1600

Lot No.

Mouse anti-Cyclin E

FORM

This monoclonal antibody is highly purified from mouse ascites by protein-A affinity chromatography. The antibody is supplied as a 400 µl aliquot at a concentration of 0.5 mg/ml in PBS (pH 7.4) containing 0.1% sodium azide.

CLONE: HE12

ISOTYPE: IgG₁-κ

IMMUNOGEN

Full-length, recombinant, human cyclin E protein.

SPECIFICITY

This antibody is specific for cyclin E. The epitope is located within the last 80 aa of the C-terminal⁽¹⁾. HE12 antibody detects a ~50 kDa band on human HeLa cell lysates by Western blot analysis.

REACTIVITY

This antibody reacts with human cyclin E (HeLa cells). Reactivity with other species has not been tested.

USAGE

The dilutions listed below are good starting points. However, optimal dilutions should be determined by the investigator for each application.

Western Blotting⁽¹⁾: 1 – 2 µg/ml

Immunoprecipitation⁽¹⁾: 1 µg/IP

Flow cytometry^(8,9):

Immunohistochemistry⁽¹⁰⁾:

Gel Mobility Shift Assay:

STORAGE

Store at 2-8°C for up to one month. Aliquot and store at -20°C for long term storage. Avoid repeated freezing and thawing.

BACKGROUND

Cyclin E is a cell cycle protein that complexes with cdk2 and is required for DNA synthesis⁽²⁾. Cyclin E/cdk2 activity peaks just before S phase. Cyclin E expression is mediated by E2F and is cleared by the ubiquitin proteolytic pathway after phosphorylation. Alterations in cyclin E expression in cancer has been correlated with increasing stage and grade of tumor. These results suggest that cyclin E may be useful as a prognostic marker for breast cancer^(3,4) and gastric cancer⁽⁵⁾, and non-small cell lung cancer⁽⁶⁾.

(cont'd)

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI321600

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

REFERENCES

1. Seghezzi W, Chua K, Shanahan F, Gozani O, Reed R, Lees E. Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells. *Mol Cell Biol.* 18(8):4526-36 (1998).
2. Koff, A, Cross, F, Fisher, A, Schumacher, J, Leguellec, K, Philippe, M, Roberts, J. M. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. *Cell* 66:1217-1228 (1991).
3. Nielsen NH, Arnerlov C, Cajander S, Landberg G. Cyclin E expression and proliferation in breast cancer. *Anal Cell Pathol.* 17(3):177-88 (1998).
4. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. *Cancer Res.* 54(2):380-5 (1994).
5. Aoyagi K, Koufujii K, Yano S, Murakami N, Terasaki Y, Yamasaki Y, Takeda J, Tanaka M, Shirouzu K. Immunohistochemical study on the expression of cyclin D1 and E in gastric cancer. *Kurume Med J.* 47(3):199-203 (2000).
6. Mishina T, Dosaka-Akita H, Hommura F, Nishi M, Kojima T, Ogura S, Shimizu M, Katoh H, Kawakami Y. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. *Clin Cancer Res.* 6(1):11-6 (2000).
7. Spruck, C. H, Won, K.-A, Reed, S. I. Deregulated cyclin E induces chromosome instability. *Nature* 401:297-300 (1999).
8. Gong J, Traganos F, Darzynkiewicz Z. Threshold expression of cyclin E but not D type cyclins characterizes normal and tumour cells entering S phase. *Cell Prolif.* 28(6):337-46 (1995).
9. Darzynkiewicz Z, Gong J, Juan G, Ardelit B, Traganos F. Cytometry of cyclin proteins. *Cytometry.* 25(1):1-13 (1996). Review.
10. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. *Cancer Res.* 59(10):2470-6 (1999).

RELATED PRODUCTS

Product	Clone	Cat. No.
Mouse anti-Cyclin E	HE172	32-1500
Mouse anti-Cyclin A	E23	33-4900
Mouse anti-Cyclin A	E67	33-4800
Mouse anti-Cyclin D1	AM29	33-3500
Mouse anti-Cyclin D1	AM69	33-3600
Rat anti-Cyclin D1	D1-17A6-4	13-5600
Mouse anti-Cyclin D1	DI-72-13G	13-4500
Immunoassay reagents		
Goat anti-Mouse IgG (H+L) (ZyMAX™ Grade)	Purified	81-6500
	FITC	81-6511
	TRITC	81-6514
	Cy™3	81-6515
	Cy™5	81-6516
	HRP	81-6520
	AP	81-6522
	Biotin	81-6540
Goat anti-Rabbit IgG (H+L) (ZyMAX™ Grade)	Purified	81-6100
	FITC	81-6111
	TRITC	81-6114
	Cy™3	81-6115
	Cy™5	81-6116
	HRP	81-6120
	AP	81-6122
	Biotin	81-6140
Protein A	Sepharose® 4B	10-1041
rec-Protein G	Sepharose® 4B	10-1241

Zymed® and ZyMAX™ are trademarks of Zymed Laboratories Inc. Cy™ is a trademark of Amersham Life Sciences, Inc. Sepharose® is a registered trademark of Pharmacia LKB.

For Research Use Only

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI321600

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.